We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tt Electronics Plc | LSE:TTG | London | Ordinary Share | GB0008711763 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.00 | 2.38% | 172.00 | 173.00 | 175.00 | 172.00 | 165.00 | 166.50 | 262,683 | 14:31:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 613.9M | -11.8M | -0.0670 | -25.52 | 300.96M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/9/2020 16:55 | "We know Alphaville readers sometimes like to really get into the weeds with this kind of story, so do watch this space for some extra bits in the coming day or two" 🤔 | imastu pidgitaswell | |
16/9/2020 16:28 | If you need a bit of entertainment to get you through hump day, might we recommend a story out today over on the main site by this Alphavillain and the FT’s excellent Anna Gross. It’s a strange tale about an obscure four-person start-up called iAbra based in a sleepy English village that reckons it has come up with a test for Covid-19, manufactured by listed company TT Electronics, that can give an accurate result in under 20 seconds. | zho | |
16/9/2020 15:32 | 5% of the register traded hands over the past few days on this fake news. A lot of people out of the money and very unhappy. Definitely needs a stewards enquiry - to sort of quote Mark Twain - there are lies, damn lies and statistics. Appears to me to be an apt motto for the TT IR department. | b0risj0hns0n | |
16/9/2020 14:41 | 74tom, but there is a company who are about to reveal a real time testing kit that does work and that has been validated. | monkey puzzle | |
16/9/2020 14:40 | I saw the 1 Sept RNS and wondered whether it warranted an RNS at all. I then saw the 2nd RNS and thought fair enough, that's a sizeable opportunity. Reading all this latest stuff leaves me wondering just how competent the management team is! Hopefully clarification RNS very soon. | overeager | |
16/9/2020 14:26 | If the device hasn't actually been tested for sensitivity / specificity then good luck to them, as they're going to need it. Bristol Uni distancing themselves from test involvement & Intel removing an article on it's website makes it look like they jumped the gun in a major way here. Add in Lord Global's Bigfoot & it has the makings of a movie script. You've always got to think, if it was this easy, surely an IBM / Apple / any other international blue chip or private enterprise would have come out with this solution months ago. An interesting story to follow from the outside looking in. | 74tom | |
16/9/2020 13:40 | I agree. Doesn't smell good at all. I suspect there are some management options maturing that require the share price to be materially higher for 2020 - and given the awful company performance through the corona pandemic, they sat round the board table and came up with a cunning plan. Amazing what suckers there are out there....... | b0risj0hns0n | |
16/9/2020 13:37 | Oh dear. Stand by for the Director shareholding RNSs. Talk about leaving a trail - if anyone has made money out of trading this, they will be in deep trouble... Quite funny though. Not confident of the CEO's prospects here... | imastu pidgitaswell | |
16/9/2020 13:24 | Full article here via MSN if the FT is complicated/paywall: You couldn't make it up: Lord Global Corporation, formerly called Bigfoot Projects Inc, is financing the distribution of Virolens machines in Australia, Latin America and south-east Asia through KeyOptions, an Australian firm that “helps provide meaningful metrics that have impact on your operations and profitability as well as keeping people safe and secure”, according to its website. Joseph Frontiere, chief executive of Lord Global, told the FT he had taken over control of the listed company this year and it was now an entirely separate operation with no connections to the former business. It is in the process of changing the entity’s name to 27Health Inc, subject to approval from US regulators. Lord Global’s “chairman of the board” — and indeed the only other person working at the company — is 24-year-old Alexandra Aizenshtadt, who is Mr Frontiere’s wife. Ms Aizenshtadt’s LinkedIn profile explains that she “enjoys a strong worldview and deep background analysing trends and communicating their complex concepts”. | edmondj | |
16/9/2020 12:22 | Huge short position in this now, if the company RNS that they have had a bona fida test carried out this will be a great buy. If it gets back to 200p I reckon its worth a punt. | czar | |
16/9/2020 11:31 | Please see extracts from the (See full link to access the report) Extracts: iAbra touted Heathrow as its ‘launch customer’ but doubts arise over the technology None of the other employees has any expertise in viruses or microscopy, though one has a PhD in physics. Before iAbra changes the world, it has to prove its product’s reliability, which has not yet received any external regulatory validation. Nor does there seem to have been any oversight of the underlying data for the company’s claims for the test’s accuracy. One scientist said he was immediately concerned by the wording of the company’s release, which suggested that the virus is “another cell”, and therefore showed “either carelessness or frightening ignorance” iAbra sent the FT a presentation with some information on the methodology used to check the accuracy of the tests, though several scientists said it did not contain enough information to explain how the company had reached its conclusions on the test’s specificity and sensitivity Academics at the University of Bristol said they were not involved in any study that tested the sensitivity and specificity of the tests and complained about the wording of the release. Bristol university virologist David Matthews only provided samples of the Covid-19 virus to the company and was not in any way involved in its validation, he said. But it is not entirely clear how the company calculated the test’s accuracy, and it seems that it may have misrepresented the involvement of virologists at the University of Bristol. Jon Deeks, professor of biostatistics at Birmingham university, said, “we are in a pandemic, people are dying from the disease, and a company decides that it is reasonable to mislead us all to make their test look like the best thing available”, referring to the claims being made for the test’s accuracy. Is the company with a 20-second coronavirus test for real? | euclid5 | |
16/9/2020 09:23 | Last week's huge rise looking a bit naive | oliver_m_j | |
16/9/2020 08:48 | At this sort of valuation TT must be close to developing a vaccine! 20x ebit for a business that makes circuit boards, with low margins and a constant stream of exceptional items. Crazy times. | reddevils1 | |
16/9/2020 08:23 | Is the company with a 20-second coronavirus test for real? | zho | |
15/9/2020 09:47 | According to a news article I found on the web - I couldn't see most of it, mainly behind a paywall - the virolens test may be more accurate than the PCR test...... ......One, by British AI specialists iAbra, uses microscopic holographic imaging to “see” Covid-19 molecules and produces results with 99.5 per cent accuracy in 20 seconds. The test, validated as 99.8 per cent accurate by Bristol University, is claimed to be 50 times more sensitive than the current PCR test used by the NHS which means that it could detect Covid-19 infections far earlier before people displayed symptoms. It remains to be seen how well it turns out, whether these claims are realistic and whether or not it sells in sufficient quantities to make a big difference? I am hoping that the share price slips a bit to allow me to add to my small holding - but its remaining remarkably strong at the moment, cheers | illiswilgig | |
15/9/2020 09:00 | False positive is a minor issue, IMO. You employ a two stage system with any positives receiving a second test - either the same equipment or a more reliable second stage. G. | garth | |
14/9/2020 22:40 | Previous posters negativity is unfounded .Not even the gold standard PCR test is 100% sensitive or specific and as good as it is may always be compromised by poor nasal swab sampling technique giving up to 30% false negatives .Saliva is the way forward for PCR. Virolens is novel and a mind blowing technology and can be evolved further just when its needed for mass testing ,No matter what test you have people must also comply with the government guidance on preventing the spread of disease in all settings to account for any false postive or negative thrown up in any testing regime | prion | |
14/9/2020 12:24 | I don't agree, its not the false negatives that are the problem but the false positives which could impair the usability of a rapid test. Lets assume its only 90% accurate ( with regards to false negatives) and the infection rate is on the high side i.e. 20 per 100000. So a test for example applied before getting on a flight would reduce the odds of an infected person on the flight to 2 per 100000 ie 0.002%. in reality the risk would be even lower as most sensible people would not fly (out) if they know they are infected. Now however careful you are you can't isolate completely so likelyhood is we would still be faced with the same risk if we were under lock-down conditions. So whats better, lock down or a 90% accurate RCT? However considering that virtually everyone tested will be negative, any significant number of false positives will create a problem as they will need to be held back from boarding , and if they still wished to fly they would need to undertake a more accurate perhaps long delay test, they and their family be put in accommodation whilst the test is processed and if the original test was incorrect be appropriately compensated. | rogerrail | |
14/9/2020 11:25 | Agree, it's never going to be acceptable for 1 in 100 passengers to receive a false negative or 3 in 100 to receive a false positive (and 2 weeks quarantine). Mobile PCR platforms using saliva rather than swabs from the nose / throat which provide results in under 1 hour would be a much better solution. Submit your test at check in, once confirmed as negative you can fly. Their accuracy is unrivalled & they are seen as gold standard around the world. | 74tom | |
14/9/2020 08:58 | This announcement reminds me of Carlco. Announce some new revolutionary tech that never materialises; to cover up the poor state of the underlying business. The problem with testing is that all of these devices still have too many false negatives - so that if 1 person in a 1000 in a busy airport goes undetected - they are free to infect all the others and the testing was a complete waste of time. Pumping a share price like this smells of management desperation to me. | reddevils1 | |
11/9/2020 09:16 | If it works it could make this fly . Worth a bet so I have bought | juju44 | |
11/9/2020 08:58 | people taking profits ,and well done to them ,will now watch ttg ,have invested more in ncyt higher percentage than usually do for September news ,was red this morning now money going in there again will be watching ttg more in future | bunz3 | |
11/9/2020 08:54 | TTG, trades so far......... Trades 233 Vol. Sold 72,189 Sold Value £199.24k Vol. Bought 149,504 Bought Value £412.63k PE Ratio 26.038 Earnings 10.60 Dividend 2.10 Yield 0.761% | 3rd eye | |
11/9/2020 08:43 | TTG..well worth a listen. | 3rd eye |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions